Left bar

About Modigene

We are a biopharmaceutical company utilizing patented technology to develop longer-lasting, proprietary versions of already approved therapeutic proteins that currently generate billions in annual global sales.

CTP Competitive Advantages

The creation of a successful, non-toxic and non-immunogenic long-lasting therapeutic protein is a very "tricky" process. The more the modified protein looks like the authentic molecule, the less toxic it is, and the less immunogenic - however this protein will break apart as quickly as the authentic molecule.

The Story Of FSH-CTP

Follicle Stimulating Hormone ("FSH") is a hormone that naturally exists in females. Women who have fertility problems may get supplemental FSH to increase the likelihood of pregnancy. Women have to be injected daily, for seven days, with FSH, at around ovulation time. The FSH market is significant, with more than $1.0 billion in 2007.
Latest News
6/30/2009 PROLOR BIOTECH AWARDED TWO U.S. PATENTS FOR ITS LONGER-ACTING HUMAN GROWTH HORMONE AND LONGER-ACTING ERYTHROPOIETIN
6/12/2009 MODIGENE SHAREHOLDERS APPROVE COMPANY NAME CHANGE AND OTHER PROPOSALS AT ANNUAL MEETING
Company’s New Name is PROLOR Biotech, Inc. Will Now Trade under New Ticker PBTH. Shareholders Approve Re-Election of Board of Directors and Other Proposals
3/10/2009 MODIGENE TO PRESENT AT THE BIO-EUROPE SPRING® 2009 CONFERENCE
2/10/2009 MODIGENE SETS RECORD DATE FOR ANNUAL MEETING OF SHAREHOLDERS
1/27/2009 MODIGENE AWARDED SECOND-YEAR GRANT BY ISRAELI GOVERNMENT TO SUPPORT DEVELOPMENT OF ITS LONGER-ACTING HUMAN GROWTH HORMONE
hGH-CTP Development Program Has Been Approved For Second-Year Funding Through a Special Grant From the Israeli Office of the Chief Scientist
1/15/2009 MODIGENE ANNOUNCES POSITIVE RESULTS OF PILOT TOXICITY STUDY OF ITS LONG-ACTING HUMAN GROWTH HORMONE HGH-CTP
Single Injection in Primates Containing 1,000-Times the Dosage Recommended for Humans Shows No Adverse Effects. Half-Life and AUC Support the Potential for Weekly or Bi-Monthly Dosing Frequency
12/31/2008 Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alpha (FSH-CTP)
9/22/2008 Modigene Publishes Letter To Shareholders
9/15/2008 MODIGENE TO PRESENT AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE
8/5/2008 MODIGENE AWARDED ISRAELI GOVERNMENT GRANT TO SUPPORT DEVELOPMENT OF ITS LONGER-ACTING INTERFERON BETA
7/16/2008 CTP is "best-of-breed" for enhancing protein longevity, In-Pharma Technologist, By Gareth Macdonald
7/10/2008 MODIGENE PLATFORM VALIDATED IN INDEPENDENT PHASE III TRIAL OF CTP TECHNOLOGY
Validates the Clinical Utility of Modigene’s CTP Technology for Extending the Duration of Action of Therapeutic Proteins
7/8/2008 Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Corifollitropin alfa meets primary endpoints in ENGAGE Trial
3/31/2008 Globes: Phillip Frost leads investment in another Israeli biomed co.
The Frost Group LLC, controlled by Dr. Phillip Frost, is making its second investment in Israel, leading a $12 million in ModiGene Inc.
3/5/2008 Modigene Names Frost Chairman, South Florida Business Journal
Miami entrepreneur Dr. Phillip Frost has been named chairman of Modigene, an Israeli company he and some associates bought a large stake in last May.
6/20/2007 Technology for long-acting proteins here to stay, InPharna Technologist.com, by Katrina Megget
Modigene's technology however, takes a mother nature approach to finding a long-lasting solution. This would be a stark therapeutic contrast to the three-plus a week injections required with the currently marketed drugs.
6/20/2007 BioCheck: Modigene: A New Biotech With Impressive Genes, StockHouse Editorials, by Leon Hamerling and J. Paul
Combining Phil Frost's track record with all the factors we've touched on above, Modigene clearly is one of the new crop of biotech companies going public that investors should be aware of.
בניית אתריםWeb Building
 Copyright 2006 © Modigene Inc. All rights reserved